A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
Price : $35 *
At a glance
- Drugs Famitinib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 01 May 2018 Status has been changed to completed.
- 17 Apr 2013 New trial record